Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could predict kidney transplant success without needles

NCT ID NCT07645599

Diagnosis Sponsor: Roderick Tan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow in tiny vessels of transplanted kidneys. The goal is to see if changes in these vessels can predict how well the kidney will work early after transplant, including delayed function. The study involves 40 adult kidney transplant recipients and uses an FDA-approved contrast agent. If it works, this could become a safe, noninvasive way to check kidney health without biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ultrasound contrast agent (lipid microspheres) and super-resolution ultrasound imaging
What this could lead to
If successful, this imaging technique could help doctors predict how well a transplanted kidney will work early on, reducing the need for invasive biopsies.
What could go wrong
This is a very small pilot study (40 people) testing a new imaging method, so it may not prove reliable or widely useful. The technique is still experimental and not yet ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with end stage kidney disease who are receiving deceased donor kidney allograft transplants who meet the inclusion and exclusion criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For stage 1 of the study: 1. We will enroll patients ≥18 years of age 2. Patients who received a kidney transplant 2a. Patients requiring dialysis in the first 14 days after transplant 2b. Patients with working allografts not requiring dialysis (control group) For stage 2 of the study 1. We will enroll patients at least 18 years of age or older 2. Patients who received a kidney transplant 2a. Patients who received kidney transplants from low KDPI kidneys (KDPI \< 35) 2b. Patients who received kidney transplants from high KDPI kidneys (KDPI \> 75) Exclusion Criteria: 1. BMI \> 40 2. Inability to provide informed consent 3. Pregnant woman 4. Breastfeeding women 5. Hypersensitivity to perfluten lipid microsphere and components including polyethylene glycol (PEG) 6. Unstable cardiopulmonary condition (acute myocardial infarction, acute coronary artery symptoms, worsening or unstable congestive heart failure, serious ventricular arrhythmias). 7. Known history of cardiac shunts 8. Patients who have known sickle cell disease or trait

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage chronic renal failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome Delayed Graft Function end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage chronic renal failure Microvascular changes Microvascular circulation Renal transplant

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.